NASDAQ:IDRA up more than 60% pre-market on positive results!

(Nasdaq: IDRA) today shared positive interim results from Amsterdam UMC, Vrije Universiteit Amsterdam, the Netherlands, regarding its investigator-sponsored trial, INTRIM 1, involving tilsotolimod, Ideras synthetic Toll-like receptor 9 agonist. Based on these results, the trial has been stopped early.

XTON, Pa., May 17, 2022 (GLOBE NEWSWIRE) — Idera Pharmaceuticals, Inc. (Idera, we, and our) (Nasdaq: IDRA) today shared positive interim results from Amsterdam UMC, Vrije Universiteit Amsterdam, the Netherlands, regarding its investigator-sponsored trial, INTRIM 1, involving tilsotolimod, Ideras synthetic Toll-like receptor 9 agonist. Based on these results, the trial has been stopped early.

https://www.globenewswire.com/news-release/2022/05/17/2444956/33448/en/Idera-Pharmaceuticals-Shares-Positive-Results-from-Investigator-Sponsored-Trial-in-Melanoma-Patients-at-Amsterdam-UMC.html

Signup today for free and be the first to get notified of breaking news.

SIGN UP FOR OUR NEWSLETTER

Sign up for Breaking Alerts, our newsletter putting timely and updated stock and crypto markets news into your hands.

Add New Playlist